期刊文献+

Notch-mTOR信号介导的免疫反应与能量代谢轴:中医药预防IBD复发的可能关键 被引量:1

Axis of immune response and energy metabolism mediated by Notch/mTOR signaling pathway: Pivotal mechanism of traditional Chinese medicine for preventing inflammatory bowel disease
下载PDF
导出
摘要 炎症性肠病(inflammatory bowel disease,IBD)是世界性难治性疾病,其难治在于高复发率.中医药治疗IBD疗效高且复发率低,但作用机制不明,然Notch与mTOR信号间相互关联,且通过各种途径调控机体免疫水平和细胞能量代谢变化,并与IBD的发作密切相关,提示调控Notch-mTOR信号介导免疫与能量轴变化可能是探索中医药预防和防止IBD复发的可能突破口和有效策略. Inflammatory bowel disease (IBD) is a kind of worldwide refractory disease with a high recurrence rate. However, traditional Chinese medicine for IBD is associated with a better therapeutic effect and a lower recurrence rate, although the mechanism is still unclear. It is known that the Notch signaling pathway interacts with mTOR and regulates the body's immune level and cell energy, which is closely related with morbidity of IBD. These hint that axis of immune response and energy metabolism mediated by the Notch/mTOR signaling pathway is possibly a pivotal mechanism for traditional Chinese medicine to prevent IBD.
出处 《世界华人消化杂志》 CAS 2016年第17期2617-2624,共8页 World Chinese Journal of Digestology
基金 国家自然科学基金资助项目 Nos.81460679 81260595 2014年度国家留学基金委地方合作基金资助项目 Nos.201408360106 201408360110~~
关键词 NOTCH 哺乳动物雷帕霉素靶蛋白 炎症性肠病 免疫 能量代谢 中医药 Notch Mammalian target ofrapamycin Inflammatory bowel disease Immune Energy metabolism Traditional Chinese medicine
  • 相关文献

参考文献15

二级参考文献169

  • 1韩英.溃疡性结肠炎的临床维持缓解治疗评价[J].中国医院用药评价与分析,2004,4(6):338-341. 被引量:13
  • 2陈治水,危北海,张万岱,李道本.溃疡性结肠炎中西医结合诊治方案(草案)[J].中国中西医结合消化杂志,2005,13(2):133-136. 被引量:182
  • 3Hirohat S, Ohshima N,Yanagida T,et al. Regulation of human B cell function by sulfasalazine and its metabolites[J]. Int Immunopharmacol, 2002,2(5) 631-640.
  • 4Park SH,Kim YM,Yang SK, et al. Clinical features and natural history of ulcer- ative colitis in Korea[J]. Inflamm Bowel Dis, 2007,13(3) :278-283.
  • 5Gisbert JP, Linares PM, McNicholl AG,et al. Meta2analysis:the efficacy of azathiop fine and mercap topurine in ulcerative colitis [J].Aliment Pharmacol Ther, 2009, 30(2):126-137.
  • 6Leite S, Ribeiro JM, Lima SC, et al. Azathiop rine in inflammatory bowel disease [J]. Acta Med Port, 2009,22(1) 133-40.
  • 7Fraser AG,Orchard TR, Jewell DP. The efficacy of azathiop rine for the treatment of inflammatory bowel disease: a 30 year review [J]. Gut, 2002,50 (4) : 485-489.
  • 8Actis GC, Fadda M, David E, et al. Colectomy rate in steroidrefrac tory colitis initially responsive to cyclosporin, a long term retrospective cohort study[J]. BMC Gastroenterol,2007,27(1) :7 13.
  • 9Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid dependent inflammatory bowel disease-a long-term follow-up[J]. Am J Gastroenterol, 2006,101 (5):1048 1056.
  • 10Rutgeerts P, Sandborn WJ , Feagan BG, etal . Infliximab for in duction and maintenance therapy for ulcerative colitis[J]. N Engl J Med,2005,353(23) :2462 -2476.

共引文献134

同被引文献8

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部